SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is experiencing high volatility as investors weigh strong revenue growth and a massive $104 billion backlog against ongoing concerns regarding high capital expenditures and debt. The community remains deeply divided, with bulls pointing to accelerating AI infrastructure demand while bears express skepticism over sustained cash burn and profitability.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is seeing significant social media activity following an earnings report that featured a revenue guidance raise and bottom-line outperformance, fueling intense debate between bulls citing AI demand and shorts highlighting governance concerns. Investors are actively discussing the stock's volatility and the disparity between its strong financial outlook and its relatively subdued market reaction.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors aggressively monitor the highly anticipated 80th event trigger for its REGAL Phase 3 clinical trial, with community sentiment sharply divided between buyout speculation and skepticism over the extended trial timeline. The company's recent filing highlighting strong cash reserves, minimal dilution, and expanded preclinical work in pancreatic cancer has intensified community debate, as traders weigh these bullish fundamentals against the binary risks of an imminent final analysis.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony ($UAMY) is trending following a significant quarterly revenue miss and a reduction in full-year guidance, which has fueled widespread investor frustration and concerns over management's execution. While some in the community see the current price drop as a discount for long-term holders, others are actively debating the company's reliance on government contracts and the lack of clarity regarding its strategic pivot toward domestic independence.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Firefly Aerospace is seeing increased trading activity as investors speculate on potential government contracts and upcoming earnings, with the community closely tracking its competitive position relative to other major players in the space sector. Market participants are actively discussing the impact of broader industry developments and heavy institutional interest as the stock navigates a volatile period leading into its next financial update.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is seeing elevated volatility as investors weigh strong earnings and data center demand against sector-wide concerns, including potential trade restrictions on optical components. The community remains divided, with many traders actively discussing the stock's long-term growth prospects as a photonics leader versus the risk of a technical correction.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending following a strong quarterly earnings report that featured a double beat on revenue and earnings, driven by robust store traffic and growth in same-restaurant sales. The community is actively debating the stock's premium valuation versus its long-term potential as a category-leading national brand, while investors closely monitor institutional sentiment and guidance.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is trending following impressive quarterly earnings that featured strong revenue growth and increased financial guidance, driving significant investor optimism. The community is actively discussing the company's manufacturing expansion and its role in critical defense and aerospace supply chains, with many expressing bullish sentiment on its long-term growth potential.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors weigh explosive demand for AI infrastructure against concerns over high capital expenditures and dilution risks, with the community closely tracking upcoming earnings for validation. The stock remains a focal point for intense debate, as market participants actively bet on a potential short squeeze while monitoring the influence of high-profile short-sellers and institutional stake-building.

NextNav, Inc. engages in development of positioning, navigation, and timing solutions. Its products include NextNav Pinnacle, NextNav 3D, and NextNav TerraPoiNT. The company was founded by Ganesh Pattabiraman and Arun Raghupathy in May 2021 and is headquartered in Reston, VA.

NextNav Inc

NextNav is trending due to heightened investor anticipation surrounding the FCC's potential approval of its spectrum reconfiguration, which remains a key catalyst despite recent legislative and industry-driven delays. The community is actively debating the significance of ongoing regulatory processes and spectrum valuation, with sentiment currently split between high-conviction bullishness regarding the company's PNT technology and concerns over the complex, long-term political hurdles.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million PR Newswire SAN DIEGO, July 16, 2026 SAN DIEGO, July 16, 2026 /PRNewswire/ -- Inhibrx...

Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice

Does Inhibrx Biosciences, Inc. (INBX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma PR Newswire SAN DIEGO, June 15, 2026 No filing review issues identified by FDA with PDUFA...

Inhibrx Reports First Quarter 2026 Financial Results

Inhibrx Reports First Quarter 2026 Financial Results Inhibrx Reports First Quarter 2026 Financial Results PR Newswire SAN DIEGO, May 14, 2026 SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx...

Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study

Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study...

Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study

Inhibrx Biosciences shares rise after Phase 2 INBRX-106 and Keytruda data showed stronger response rates in head and neck cancer.read more...

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy Inhibrx Reports Interim Phase 2 Data for...

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon...

Credit Industriel ET Commercial Sells 20,302 Shares of Inhibrx Biosciences, Inc. $INBX

Credit Industriel ET Commercial decreased its position in Inhibrx Biosciences, Inc. (NASDAQ:INBX - Free Report) by 70.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,656 shares of...

Inhibrx Biosciences, Inc. (NASDAQ:INBX) Receives Average Rating of "Hold" from Brokerages

Inhibrx Biosciences, Inc. (NASDAQ:INBX - Get Free Report) has received an average recommendation of 'Hold' from the six brokerages that are currently covering the firm, MarketBeat.com reports. One...

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Inhibrx Biosciences Inc.

INBX Stock Hit Record Highs: Cancer Therapies Reportedly Draw Big Pharma Interest

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

INBXInhibrx Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest INBX News